Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
Evy UlijnNathan den BroederMaike WientjesNoortje van HerwaardenInger MeekLieke TweehuysenAatke van der MaasBart Jf van den BemtAlfons A den BroederPublished in: Annals of the rheumatic diseases (2020)
In contrast to earlier research, we could not find predictive value for response to a second TNFi or non-TNFi for either ADA or random timed ADL.